Type II variation [Regulatives / Guidelines]

posted by Helmut Homepage – Vienna, Austria, 2018-06-22 15:12 (853 d 07:58 ago) – Posting: # 18948
Views: 5,613

Hi Beholder,

» […] whether we need to perform BEQ study in case of changes in amount of tablets in production batch or not? I refer to the table B.II.b.4 Change in the batch size (including batch size ranges) of the finished product

Yes because that’s a Type II (i.e., a major) variation. Only if the conditions for a bio­waiver are applicable you could get around an in vivo study.

Dif-tor heh smusma 🖖
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

Activity
 Admin contact
21,177 posts in 4,414 threads, 1,474 registered users;
online 8 (1 registered, 7 guests [including 5 identified bots]).
Forum time: Thursday 23:11 CEST (Europe/Vienna)

It is not so much that I have confidence in scientists being right,
but that I have so much in nonscientists being wrong.    Isaac Asimov

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5